European Medicines Agency re-org
This article was originally published in The Tan Sheet
Executive SummaryA major re-organization of the EU agency streamlines human drug pre- and post-authorization activities into one unit, creates a patient health protection unit and designates a group to manage product data and documentation, the agency announces Dec. 8. The changes respond to increased responsibilities proposed in legislation, the agency said. The regulator, which dropped its acronym EMEA because the second "e" confused stakeholders, plans to launch in early 2010 a redesigned Web site with improved search and navigation functions
You may also be interested in...
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.
Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.